Literature DB >> 27751840

Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.

Mamatha Bhat1, Peter Ghali1, Benoît Dupont1, Roy Hilzenrat2, Mahmood Tazari3, André Roy4, Prosanto Chaudhury5, Fernando Alvarez6, Michel Carrier7, Marc Bilodeau8.   

Abstract

BACKGROUND & AIMS: Patients listed with exception points for hepatocellular carcinoma (HCC) have been more likely to be transplanted than those listed for chronic liver failure (LF) based on the model for end-stage liver disease (MELD) score. The aim of this study was to determine outcomes in the 5-year experience of a scoring system designed to reflect heterogeneity of tumor load of patients listed for HCC.
METHODS: A novel MELD exception point system based on size and number of HCC was implemented in July 2009. This system allows stratification of patients based on risk of dropping out from the waiting list according to Milan criteria. LF patients were listed according to biological MELD sodium score; HCC patients were reassigned points every three months upon repeat imaging.
RESULTS: Among 624 patients listed for liver transplant (LT), 505 were eligible. 94 (18.6%) were assigned MELD HCC points. Only 24.7% required changes in allocated points over time. Transplantation rates (HCC 83% vs. LF 73%, p=0.04) and waiting time in days (HCC 258 vs. LF 325; p=0.07) were similar. The method of competing risk analysis revealed that HCC patients were more likely to be transplanted than LF during the 5-year period preceding implementation, whereas transplant rates became equivalent for HCC and non-HCC in 2009-2014. One- and two-year survivals were similar between the two groups.
CONCLUSIONS: Our study demonstrates that a novel MELD point system for HCC, taking into account dynamics in tumor size and number, allows for equitable liver allocation without compromising graft and patient survival. LAY
SUMMARY: It has historically been difficult to achieve equitable liver allocation for liver cancer and chronic liver failure with the allocation systems currently in place in many countries worldwide. We designed a new system to help improve access to organs for liver failure patients in Québec, Canada. Our 5-year experience demonstrates that this unique system renders access to transplant similar for both liver cancer and liver failure indications.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Exception points; Hepatocellular carcinoma; Liver transplantation; Malignancy; Organ allocation

Mesh:

Year:  2016        PMID: 27751840     DOI: 10.1016/j.jhep.2016.10.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

Review 1.  Transplantation for hepatocellular cancer: pushing to the limits?

Authors:  Quirino Lai; Alessandro Vitale
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

2.  Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation.

Authors:  Neil Mehta; Jennifer L Dodge; Ryutaro Hirose; John P Roberts; Francis Y Yao
Journal:  Am J Transplant       Date:  2019-04-05       Impact factor: 8.086

3.  Development of a Korean Liver Allocation System using Model for End Stage Liver Disease Scores: A Nationwide, Multicenter study.

Authors:  Juhan Lee; Jae Geun Lee; Inkyung Jung; Dong Jin Joo; Soon Il Kim; Myoung Soo Kim
Journal:  Sci Rep       Date:  2019-05-16       Impact factor: 4.379

4.  Machine learning to predict waitlist dropout among liver transplant candidates with hepatocellular carcinoma.

Authors:  Allison Kwong; Bilal Hameed; Shareef Syed; Ryan Ho; Hossein Mard; Sahar Arshad; Isaac Ho; Tashfeen Suleman; Francis Yao; Neil Mehta
Journal:  Cancer Med       Date:  2022-01-14       Impact factor: 4.452

5.  The predictive value of MELDNa (model for end-stage liver disease-sodium) and mean platelet volume/platelet count for patients' 30-day mortality after liver transplantation.

Authors:  Vecihe Bayrak; Mehmet Çağatay Gürkök; Ferhan Demirer Aydemir; Bişar Ergün; Tufan Egeli; Nurcan Şentürk Durukan; Tarkan Ünek; Necati Gökmen
Journal:  Clin Exp Hepatol       Date:  2022-03-31

Review 6.  Hepatocellular Carcinoma-How to Determine Therapeutic Options.

Authors:  Neil Mehta
Journal:  Hepatol Commun       Date:  2020-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.